Novel epigenetic targets Educational session

7IN - Targeting histone H3K36me3-deficient cancers

Presentation Number
7IN
Lecture Time
11:35 - 11:55
Speakers
  • Timothy Humphrey (Oxford, GB)
Location
Room Scene AB, Paris Marriott Rive Gauche, Paris, France
Date
05.03.2018
Time
11:05 - 12:45
Authors
  • Timothy Humphrey (Oxford, GB)

Abstract

Background

SETD2-dependent histone H3 lysine 36 trimethylation (H3K36me3) plays a central role in both maintaining genome stability and in suppressing tumorigenesis, and is frequently depleted in particular cancer types. We find this histone mark plays an important role in promoting homologous recombination (HR) repair of DNA double-strand breaks. Further, H3K36me3 also performs an essential role in facilitating DNA replication following WEE1 kinase inhibition, through promoting efficient deoxyribonucleotide synthesis. Accordingly, H3K36me3-deficient cancers can be specifically targeted using the WEE1 inhibitor, AZD1775, resulting in replicative catastrophe and cell death. The use of AZD1775 to target H3K36me3-deficient cancers is now in clinical trials. Mechanistic insights into the targeting of H3K36me3-deficient cancers with AZD1775 and its implications will be presented.

Legal entity responsible for the study

CRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK

Funding

Medical Research Council; Cancer Research UK; Clarendon Scholarship; Swiss National Science Foundation

Disclosure

The author has declared no conflicts of interest.

Collapse